Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

BACKGROUND: Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions. This Phase 1 study (NCT03954704) evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolcher, Anthony W, Gordon, Michael, Mahoney, Kathleen M, Seto, Anna, Zavodovskaya, Marianna, Hsueh, Chia-Hsiang, Zhai, Shuyan, Tarnowski, Thomas, Jürgensmeier, Juliane M, Stinson, Susanna, Othman, Ahmed A, Chen, Tianling, Strauss, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906379/
https://www.ncbi.nlm.nih.gov/pubmed/36746510
http://dx.doi.org/10.1136/jitc-2022-005267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906379/
https://www.ncbi.nlm.nih.gov/pubmed/36746510
http://dx.doi.org/10.1136/jitc-2022-005267

Ejemplares similares